Patients with commercial insurance may be eligible for copay assistance and patients with no prescription coverage who also lack the financial resources to pay for their medicine may be eligible for participation in the patient assistance program. ... Ingrezza demonstrated a three-times greater improvement in chorea severity compared with ...INGREZZA may cause serious side effects, including: Sudden swelling from an allergic reaction (angioedema). Sudden swelling has happened after the first dose or after many doses of INGREZZA. Signs and symptoms of angioedema include: swelling of your face, lips, throat, and other areas of your skin, difficulty swallowing or breathing, and raised ...inhibitor, reduce the dose of INGREZZA to 40 mg once daily [see Dosage and Administration (2.3, 2.4)]. INGREZZA should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage.See medically reviewed information on Ingrezza. For informational purposes only. Consult a medical professional for advice.Austedo (deutetrabenazine) and Ingrezza (valbenazine) are prescription medications used to treat movement problems in Huntington's disease and tardive dyskinesia. Austedo and Ingrezza have similar active ingredients and mechanisms of action. The presence of deuterium in Austedo can impact the way the medication is broken down in the body.The molecular formula of valbenazine free base is C24H38N2O4 and its molecular weight is 418.57. INGREZZA capsules are intended for oral administration only. Each capsule contains 73 mg, 109 mg or 146 mg of valbenazine tosylate equivalent to 40 mg, 60 mg or 80 mg of valbenazine free base, respectively.Valbenazine is a medication that treats involuntary movements caused by tardive dyskinesia. This condition affects your movement and facial tics like lip-smacking and grimacing.a. The KINECT-HD pivotal study was a Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of once-daily INGREZZA in subjects with HD chorea. The study included a 4-week screening period, an 8-week dose-adjustment period, a 4-week maintenance period, and a final study visit 2 weeks ...Dive Brief: Neurocrine Biosciences will soon have its first marketed product now that the Food and Drug Administration has approved the company's lead candidate for movement disorders. Ingrezza (valbenazine) got a green light Tuesday as a treatment for adults with tardive dyskinesia (TD), a condition stemming from years of antipsychotic drug use.Like most other things these days, you can pretty easily find the names of actors in TV commercials through a simple online search. In particular, there are several websites and online resources that specialize in this kind of search. Photo Courtesy: Progressive via YouTube. Here are some of our top recommendations:You should consult your health care professional before taking any drug, changing your diet, or commencing or discontinuing any course of treatment. Valbenazine is used to treat involuntary movements of the face, tongue, or other body parts (tardive dyskinesia). This medication is also used to decr.Ingrezza. ) The US Food and Drug Administration (FDA) has approved the first medication for the treatment of tardive dyskinesia (TD), the agency said in a statement. " [TD] can be disabling and ...INGREZZA is a drug for the treatment of tardive dyskinesia. Tardive dyskinesia is a condition characterized by uncontrolled, repetitive, involuntary movements of the face, tongue, arms, legs, and ...INGREZZA ® (valbenazine) 2022 ... In connection with MTPC's first commercial sale of DYSVAL in Japan, we received a milestone payment of $20.0 million, which was recognized as revenue in the ...This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI).INGREZZA ® (valbenazine) Third Quarter Net Product Sales of $376 Million. INGREZZA ® (valbenazine) 2022 Net Product Sales Guidance Raised to $1.4 - $1.425 Billion. Supplemental New Drug Application (sNDA) of Valbenazine For the Treatment of Chorea in Patients with Huntington Disease Submitted to the U.S. Food and Drug …This new drug application provides for the use of Ingrezza (valbenazine) 40mg Capsules for the treatment of tardive dyskinesia. We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.This video sheds some light on tardive dyskinesia, my experiences with tardive dyskinesia and my experiences with Ingrezza, which is a new med to treat the m...--Neurocrine Biosciences, Inc. today announced its financial results for the third quarter ended September 30, 2023, raised 2023 net sales guidance for INGREZZA, and announced an Analyst Day to be ...INGREZZA SPRINKLE granules added to soft food can be stored for up to 2 hours at room temperature between 68°F to 77°F (20°C to 25°C). After 2 hours, throw away any unused portion. Keep INGREZZA, INGREZZA SPRINKLE and all medicines out of the reach of children.Ingrezza. Warning. If you have Huntington's disease, valbenazine can sometimes increase the risk of depression and suicidal thoughts/attempts. People with Huntington's disease are already more likely to have depression and suicidal thoughts/attempts. Talk with your doctor about the risks and benefits of this medication.Ingrezza Commercial location by The Location Portal. Connecting Premier Properties to the Film Industry Call us at (310) 928-3456 (FILM)The molecular formula of valbenazine free base is C24H38N2O4 and its molecular weight is 418.57. INGREZZA capsules are intended for oral administration only. Each capsule contains 73 mg, 109 mg or 146 mg of valbenazine tosylate equivalent to 40 mg, 60 mg or 80 mg of valbenazine free base, respectively.Ingrezza Prices, Coupons and Patient Assistance Programs. Ingrezza ( valbenazine ) is a member of the VMAT2 inhibitors drug class and is commonly used for Huntington's Disease, and Tardive Dyskinesia. The cost for Ingrezza oral capsule (40 mg-80 mg) is around $8,702 for a supply of 28 capsules, depending on the pharmacy you visit.This works out to an annual cost of $102,973 to $113,126 per year, but most people do not pay this amount. Ingrezza is also available as a one-month free trial for new patients, through the Ingrezza Start program. For more information, call 1-84-INGREZZA (1-844-647-3992) 8am to 8pm EST, Monday through Friday.It depends on which coverage stage you are in. Click on a tab below…. Deductible. Post-Deductible. Donut Hole. Post-Donut Hole. Copay Range. $55 - $8641. After your deductible has been satisfied, you will enter the Post-Deductible (also called Initial Coverage) stage, where you pay your copay and your plan covers the rest of the drug cost.Updates on INGREZZA. INGREZZA was approved for treatment of chorea symptoms in people with HD earlier this year. Research published in Clinical Therapeutics found that INGREZZA may be crushed and added to soft foods or liquids for delivery. Different methods, mediums, and temperatures were tested, and the drug maintained similar …Aug 3, 2021 ... ▫ Continued Focus on INGREZZA Commercial Execution. ▫ Grow Awareness and Adoption of ONGENTYS via. Educational Initiatives and Product ...Patients with commercial insurance may be eligible for copay assistance and patients with no prescription coverage who also lack the financial resources to pay for their medicine may be eligible for participation in the patient assistance program. ... Ingrezza demonstrated a three-times greater improvement in chorea severity compared with ...Most patients pay less than $10 out-of-pocket cost for INGREZZA. 1. You may pay as little as a $0 copay on your INGREZZA prescription. If you are eligible, a Savings Card may be applied automatically at the pharmacy, which may help you save money on your INGREZZA prescription. * Call the INGREZZA Call Center at 1-84-INGREZZA (1-844-647-3992) to ...Dive Brief: Neurocrine Biosciences will soon have its first marketed product now that the Food and Drug Administration has approved the company's lead candidate for movement disorders. Ingrezza (valbenazine) got a green light Tuesday as a treatment for adults with tardive dyskinesia (TD), a condition stemming from years of antipsychotic drug use.The program includes copay assistance for individuals with commercial insurance as well as assistance for uninsured patients. The FDA's decision comes about eight months after the agency agreed to review the company's application asking to add Huntington's-associated chorea to Ingrezza 's label, which already covered tardive dyskinesia ...SG&A guidance range reflects expense for ongoing commercial initiatives supporting INGREZZA growth including the expanded indication to treat chorea associated with Huntington's disease and pre ...INGREZZA® (valbenazine) capsules or INGREZZA® SPRINKLE (valbenazine) capsules are prescription medicines used to treat adults with: movements in the face, tongue, or other body parts that cannot be controlled (tardive dyskinesia). involuntary movements (chorea) of Huntington's disease. INGREZZA or INGREZZA SPRINKLE do not cure the cause of ...INGREZZA should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage. 5.3 Parkinsonism INGREZZA may cause parkinsonism in patients with tardive dyskinesia.The NDC code 70370-1060 is assigned by the FDA to the product Ingrezza which is a human prescription drug product labeled by Neurocrine Biosciences, Inc.. The generic name of Ingrezza is valbenazine. The product's dosage form is capsule and is administered via oral form. The product is distributed in a single package with assigned NDC code ...The Ingrezza oral granules capsules (40 mg, 60 mg and 80 mg) are intended to be opened for sprinkling on soft foods prior to administration. The NDA filing included chemistry, manufacturing, and controls (CMC) information and data demonstrating the bioequivalence and tolerability of the Ingrezza oral granule sprinkle capsules compared to the currently approved Ingrezza capsules.Jun 13, 2023 ... Qelbree Commercial (2022), "Turn the Tables ... Qelbree Commercial (2022). 2.5K views · 9 ... TakING on TD™ with INGREZZA® (valbenazine) capsules.May 4, 2022 ... commercial with Nucala. Have you seen it yet? He got a lot of screen time! We absolutely loved this location in upstate New York. What ...For Neurocrine, the decision will wrap up nearly three years of commercial struggles around the medicine. For 2022, Ongentys only brought in $13 million in sales. In the first quarter of this year ...Jul 21, 2020 · The most common side effect of Ingrezza is sleepiness (somnolence). Other common side effects include: changes in balance (balance problems, dizziness) or an increased risk of falls. headache. feelings of restlessness. dry mouth. constipation. blurred vision. These are not all of the possible side effects of Ingrezza.Company Today Also Provided Updates on R&D Portfolio and Strategy at Investor Event ; Crinecerfont New Drug Application Submission Planned in 2024Its molecular formula is C38H54N2O10S2, and its molecular weight is 762.97 g/mol (ditosylate salt) with the following structure: The molecular formula of valbenazine free base is C24H38N2O4 and its molecular weight is 418.57. INGREZZA capsules are intended for oral administration only.Aug 18, 2023 · INGREZZA demonstrated a three-times greater improvement in chorea severity compared to placebo, with a 4.6-point improvement seen with INGREZZA versus a 1.4-point improvement with placebo in the ...More recently, the company closed on a $518 million convertible note offering with a 2.25% coupon and a conversion price close to $76/share, giving the company ample cash to support ...INGREZZA can cause somnolence. Patients should not perform activities requiring mental alertness such as operating a motor vehicle or operating hazardous machinery until they know how they will be affected by INGREZZA. QT Prolongation INGREZZA may prolong the QT interval, although the degree of QT prolongation is not clinically significantApr 11, 2017 ... Commercial Real Estate · Corporate Expansion ... INGREZZATM (valbenazine) ... Please see INGREZZA full Prescribing Information at www.INGREZZA.com.Each Ingrezza Sprinkle capsule contains oral granules consisting of valbenazine, a vesicular monoamine transporter 2 inhibitor. For patients who experience dysphagia or have difficulty swallowing ...Sep 25, 2023 ... Arexvy Commercial #2 (2023). 8K views · 6 ... Commercial. Living with UC & CD•30K views · 1:01 ... TakING on TD™ with INGREZZA® (valbenazine) ...Company Today Also Provided Updates on R&D Portfolio and Strategy at Investor Event ; Crinecerfont New Drug Application Submission Planned in 2024This is a new sprinkle formulation of the once-daily capsule version of Ingrezza, which was approved previously to treat tardive dyskinesia as well as chorea associated with Huntington disease (HD). Ingrezza oral granules are designed to be packaged in 40 mg, 60 mg, or 80 mg capsules, which are then opened and sprinkled onto soft foods.Jun 21, 2023 ... Ingrezza sounds like an Italian entree, one ... But the most annoying of all is the currently ubiquitous ad ... Maybe my favorite ad is the one for ...inhibitor, reduce the dose of INGREZZA to 40 mg once daily [see Dosage and Administration (2.3, 2.4)]. INGREZZA should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage.Share this article. SAN DIEGO, April 30, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration has approved INGREZZA ® SPRINKLE ...Please see INGREZZA full Prescribing Information, including Boxed Warning. About Neurocrine Biosciences, Inc. Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company ...SAN DIEGO, Aug. 18, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration (FDA) has approved INGREZZA ® (valbenazine) capsules for the treatment of adults with chorea associated with Huntington's disease (HD). 1 INGREZZA is the only selective vesicular monoamine transporter 2 (VMAT2) inhibitor that offers an effective starting ...Using benztropine together with valbenazine may increase side effects such as dizziness, drowsiness, confusion, and difficulty concentrating. Some people, especially the elderly, may also experience impairment in thinking, judgment, and motor coordination. You should avoid or limit the use of alcohol while being treated with these medications.Commercial: Ingrezza.com. #1401226. CNN Evening News for Saturday, Sep 18, 2021. View other clips in this broadcast →. Material supplied by VTNA may be used for educational analysis or research only. Any editing, reproduction, publication, rebroadcast, public showing or public display may be prohibited by copyright laws.The initial dosage for INGREZZA is 40 mg once daily. After one week, increase the dose to the recommended dosage of 80 mg once daily. A dosage of 40 mg or 60 mg once daily may be considered depending on response and tolerability. Chorea Associated with Huntington’s Disease. The initial dosage for INGREZZA is 40 mg once daily.For both doses, the average percentage release at first and last collection time points (10 minutes and 60 minutes, respectively) was similar for whole vs crushed in each of two commercial lots of ...Preserve antipsychotic regimens. INGREZZA ® (valbenazine) capsules offers the ability to treat TD while preserving your patient’s antipsychotic regimen 4. 2013 American Academy of Neurology guidelines 5. There is a lack of clear evidence to support or refute withdrawing or switching antipsychotics to treat TD.Ingrezza; Descriptions. Valbenazine is used to treat movement disorders, including tardive dyskinesia and chorea caused by Huntington's disease. ... Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes. Share; Tweet; Advertisement. Mayo Clinic does not endorse companies or products ...1 It may be mediated through selective inhibition of VMAT2 in presynaptic neurons, with no appreciable binding affinity for VMAT1, dopaminergic receptors, or serotonergic receptors 2. 2 INGREZZA is believed to provide reversible reductions of dopamine release into the synaptic cleft 2.In a clinical study, most people began to experience improvement at 2 weeks.* Significant improvement was shown at 12 weeks vs placebo. † * Patients had at least a 1-point reduction in TMC score at 2 weeks vs before treatment. This post-clinical study evaluation included 64 patients taking INGREZZA 40 mg, measuring HD chorea before starting …For Neurocrine, the decision will wrap up nearly three years of commercial struggles around the medicine. For 2022, Ongentys only brought in $13 million in sales. In the first quarter of this year ...By blocking VMAT2, Ingrezza reduces the uptake of dopamine, causing a decrease in symptoms of TD and chorea. Ingrezza may also regulate the uptake of other neurotransmitters, such as noradrenaline and serotonin. All these neurotransmitters have various functions within the body but dopamine, in particular, plays a role in movement as well as ...Propranolol may cause vivid dreams and is... more. Ingrezza has an average rating of 5.4 out of 10 from a total of 16 ratings on Drugs.com. 44% of reviewers reported a positive effect, while 44% reported a negative effect. Propranolol has an average rating of 8.2 out of 10 from a total of 1347 ratings on Drugs.com. 77% of reviewers reported a ...It is not known if Ingrezza is safe for children. The most common side effect was sleepiness. Other side effects may include coordination problems, headache, restlessness, dry mouth, constipation, and blurred vision. Serious side effects may include heart rhythm problems and Parkinson-like symptoms.Welcome to a comprehensive exploration of Ingrezza, a medication known for its efficacy in managing specific medical conditions. In this guide, we will delve...Initial Dose: 40 mg orally once a day. Maintenance Dose: Increase to 80 mg orally once a day after one week at the initial dose; however, continuation of the initial dose may be considered for some patients. Comments: Administer with or without food. Use: Treatment of tardive dyskinesia.Neurocrine, the maker of Ingrezza, a drug for tardive dyskinesia, launched a TV spot and a website to educate patients and doctors about the condition. The company also added 80 sales reps and reported $130 million in quarterly sales for Ingrezza.INGREZZA ® (valbenazine) Second Quarter Net Product Sales of $440 Million Representing 26% Year-Over-Year Growth. INGREZZA ® (valbenazine) 2023 Net Product Sales Guidance Raised to $1.77 - $1.82 Billion. SAN DIEGO, Aug. 1, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the second quarter ended June 30, 2023 and raised net sales ...The commercial success of INGREZZA or ONGENTYS will depend upon the acceptance of those products as safe and effective by the medical community and patients. The sustainability of profitability will be a factor as government and third-party payers impose sales and pharmaceutical pricing controls on the products or limit …INGREZZA Commercial1 It may be mediated through selective inhibition of VMAT2 in presynaptic neurons, with no appreciable binding affinity for VMAT1, dopaminergic receptors, or serotonergic receptors 2. 2 INGREZZA is believed to provide reversible reductions of dopamine release into the synaptic cleft 2.INGREZZA can cause somnolence. Patients should not perform activities requiring mental alertness such as operating a motor vehicle or operating hazardous machinery until they know how they will be affected by INGREZZA. QT Prolongation INGREZZA may prolong the QT interval, although the degree of QT prolongation is not clinically significantMore about Ingrezza ( valbenazine ) Ratings & Reviews. Austedo has an average rating of 6.2 out of 10 from a total of 11 ratings on Drugs.com. 45% of reviewers reported a positive effect, while 18% reported a negative effect. Ingrezza has an average rating of 5.4 out of 10 from a total of 16 ratings on Drugs.com. 44% of reviewers reported a ...Watch, interact and learn more about the songs, characters, and celebrities that appear in your favorite Ingrezza TV Commercials. Watch the commercial, share it with friends, then discover more great Ingrezza TV commercials on iSpot.tvPlease see Important Safety Information, including Boxed Warning, below.Hear about the efficacy, safety profile, and dosing schedule of a treatment for adult...Christa in Ingrezza Commercial 2021 - YouTube. theatregal10. 38 subscribers. Subscribed. 1. 2. 3. 4. 5. 6. 7. 8. 9. 0. 1. 2. 3. 4. 5. 6. 7. 8. 9. 0. 1. 2. 3. 4. 5. 6. 7. 8. 9. No views 1 minute...Fourth Quarter and Fiscal 2022 INGREZZA Net Product Sales and Commercial Highlights:. INGREZZA fourth quarter and fiscal 2022 net product sales were $399 million and $1.43 billion, respectively; INGREZZA fourth quarter net product sales and total prescriptions grew 33% and 29%, respectively, vs. fourth quarter of 2021INGREZZA safely and effectively. See full prescribing information for INGREZZA. INGREZZATM (valbenazine) capsules, for oral use Initial U.S. Approval: 2017 -----INDICATIONS AND USAGE----- INGREZZA is a vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with tardive dyskinesia. ...The molecular formula of valbenazine free base is C24H38N2O4 and its molecular weight is 418.57. INGREZZA capsules are intended for oral administration only. Each capsule contains 73 mg, 109 mg or 146 mg of valbenazine tosylate equivalent to 40 mg, 60 mg or 80 mg of valbenazine free base, respectively.Check out Ingrezza's 60 second TV commercial, 'Movements' from the Rx: Depression, Bipolar & Insomnia industry. Keep an eye on this page to learn about the songs, characters, and celebrities appearing in this TV commercial. Share it with friends, then discover more great TV commercials on iSpot.tv. Published. October 02, 2023.For more information, you can refer to Ingrezza’s prescribing information. Mild side effects that have been reported with Ingrezza include: restlessness. back pain. blurry vision. digestive ...Ingrezza has an average rating of 5.4 out of 10 from a total of 16 ratings on Drugs.com. 44% of reviewers reported a positive effect, while 44% reported a negative effect. Tetrabenazine has an average rating of 6.4 out of 10 from a total of 6 ratings on Drugs.com. 60% of reviewers reported a positive effect, while 20% reported a negative effect.Ingrezza costs approximately $7,921 for 28 capsules of the 40mg strength and $8,702 for 28 capsules of the 80mg strength, or an annual cost of $102,973 to $113,126 per year; however, most people do not pay this amount. ... People with commercial insurance may qualify for a $0 copay for each Ingrezza prescription through the INBRACE Support ...Yes, Ingrezza with product code 70370-2040 is active and included in the NDC Directory. The product was first marketed by Neurocrine Biosciences, Inc. on December 14, 2018 and its listing in the NDC Directory is set to expire on December 31, 2025 if the product is not updated or renewed by the manufacturer.Sep 10, 2022 · About Press Copyright Contact us Creators Advertise Developers Terms Privacy Policy & Safety How YouTube works Test new features NFL Sunday Ticket Press Copyright ...buPROPion valbenazine. Applies to: bupropion and Ingrezza (valbenazine) BuPROPion may increase the blood levels and effects of valbenazine, such as sleepiness and an irregular heart rhythm problem called QT prolongation. Irregular heart rhythm problems may be serious and potentially life-threatening, although it is a rare side effect.Choose A Better Way To Measure TV ROAS. Watch, interact and learn more about the songs, characters, and celebrities that appear in your favorite Ingrezza TV Commercials. Watch the commercial, share it with friends, then discover more great Ingrezza TV commercials on iSpot.tv.Treatments for tardive dyskinesia include deutetrabenazine ( Austedo, Austedo XR ), valbenzaine ( Ingrezza ), tetrabenazine ( Xenazine ), amantadine, vitamin B6 (pyridoxine) and pyridoxal-5-phosphate, and vitamin E. The routine use of benzodiazepines should be discouraged. Other treatments may be used off-label.May 17, 2021 · TV Ad Attribution & Benchmarking. Marketing Stack Integrations and Multi-Touch Attribution. Real-Time Video Ad Creative Assessment. Ingrezza is a prescribed oral medication which is intended to treat adults who suffer from tardive dyskinesia by reducing dopamine signaling when taken regularly as suggested. Published.Screening for TD before starting or changing patients' dopamine receptor blocking agent (DRBA) treatment. 2. Monitoring for signs of TD at each visit. 3. Conducting a structured TD assessment every 6 to 12 months, depending on patient's risk, and if new or worsening movements are detected at any visit. Review full APA guidelines.. Administer INGREZZA orally with or without food [see ClinicalPharmacy Prior Authorization · A. Abilif inhibitor, reduce the dose of INGREZZA to 40 mg once daily [see Dosage and Administration (2.3, 2.4)]. INGREZZA should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage.INGREZZA® (valbenazine) capsules or INGREZZA® SPRINKLE (valbenazine) capsules are prescription medicines used to treat adults with: movements in the face, tongue, or other body parts that cannot be controlled (tardive dyskinesia). involuntary movements (chorea) of Huntington’s disease. INGREZZA or INGREZZA SPRINKLE do not cure the cause of ... Jul 21, 2020 · The most common side effect of Ingrezza is sleepi Factors that could affect your cost include: your dosage. whether you qualify and apply for any savings programs. the specialty pharmacy you choose. the supply of medication you receive (such as a ...Orsini Specialty Pharmacy (1-800-279-1676) PantherRx Rare (1-844-221-3777) Select local and community pharmacies. * If a prescription is sent to a Walgreens Community-Based Specialty Pharmacy, contact the store directly. These specialty pharmacies can dispense your Ingrezza or Ingrezza Sprinkle and will mail it directly to you via overnight mail. INGREZZA® (valbenazine) capsules. 355 subscribers. Subscribed. 5....
Continue Reading